PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer [Yahoo! Finance]
PDS Biotechnology Corporation (PDSB)
Last pds biotechnology corporation earnings: 11/7 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Second Versamune ® platform candidate targets MUC1-positive solid tumors U.S. Patent #12,201,685 covering methods of using combinations of the Versamune ® platform and various immunocytokines, including PDS01ADC recently issued PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (“IND”) application filed in January 2025 to evaluate a combination of Versamune ® MUC1 (formerly PDS0103), its novel investigational MUC1-targeted immunotherapy candidate + PDS01ADC to treat MUC1-positive unresectable, metastatic colorectal carcinoma (“mCRC”) in patients who failed previous treatment. “MUC1 is over-expressed in multiple solid tumors including colon, pancreatic, ovarian, breast, and NSCLC, and is associat
Show less
Read more
Impact Snapshot
Event Time:
PDSB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PDSB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PDSB alerts
High impacting PDS Biotechnology Corporation news events
Weekly update
A roundup of the hottest topics
PDSB
News
- PDS Biotech Announces New Composition of Matter Patent for PDS0101 in JapanGlobeNewswire
- PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)GlobeNewswire
- PDS Biotechnology (NASDAQ:PDSB) had its price target lowered by analysts at B. Riley from $5.00 to $3.00. They now have a "buy" rating on the stock.MarketBeat
- PDS Biotechnology (NASDAQ:PDSB) had its price target raised by analysts at HC Wainwright from $13.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs UpdateGlobeNewswire
PDSB
Earnings
- 11/13/25 - Beat
PDSB
Sec Filings
- 12/12/25 - Form S-8
- 12/9/25 - Form 8-K
- 12/2/25 - Form 8-K
- PDSB's page on the SEC website